Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Malignant Melanoma

  Free Subscription


Articles published in Br J Dermatol

Retrieve available abstracts of 217 articles:
HTML format



Single Articles


    June 2020
  1. HOLLESTEIN LM, Nijsten T
    Survival is excellent for most patients with thin melanoma, but patients may die from thin melanoma.
    Br J Dermatol. 2020 Jun 15. doi: 10.1111/bjd.19208.
    PubMed    


  2. OLSEN CM
    Global trends in melanoma mortality differ by sex and age.
    Br J Dermatol. 2020 Jun 8. doi: 10.1111/bjd.19166.
    PubMed    


  3. MANRIQUE-SILVA E, Rachakonda S, Millan-Esteban D, Garcia-Casado Z, et al
    Clinical, environmental, and histological distribution of BRAF, NRAS and TERT promoter mutations among cutaneous melanoma patients. A retrospective study of 563 patients.
    Br J Dermatol. 2020 Jun 7. doi: 10.1111/bjd.19297.
    PubMed     Abstract available


    May 2020
  4. JANDA M, Swetter SM, Horsham C, Soyer HP, et al
    Virtual melanoma checks during a pandemic.
    Br J Dermatol. 2020 May 29. doi: 10.1111/bjd.19255.
    PubMed     Abstract available


  5. BEHBAHANI S, Malerba S, Samie FH
    Acral Lentiginous Melanoma: Clinicopathologic Characteristics and Survival Outcomes in the United States National Cancer Database 2004 -2016.
    Br J Dermatol. 2020 May 14. doi: 10.1111/bjd.19211.
    PubMed     Abstract available


  6. TALAGANIS JA, Gregoriou S, Stratigos AJ
    Stress and melanoma. Myth or reality?
    Br J Dermatol. 2020 May 10. doi: 10.1111/bjd.19035.
    PubMed    


    April 2020
  7. LOTZ M, Budden T, Furney SJ, Viros A, et al
    Molecular subtype, biological sex and age shape melanoma tumour evolution.
    Br J Dermatol. 2020 Apr 13. doi: 10.1111/bjd.19128.
    PubMed     Abstract available


  8. PORTELLI F, Galli F, Cattaneo L, Cossa M, et al
    The prognostic impact of the extent of ulceration in clinical stage I-II melanoma patients: A multicenter study of the Italian Melanoma Intergroup (IMI).
    Br J Dermatol. 2020 Apr 13. doi: 10.1111/bjd.19120.
    PubMed     Abstract available


  9. MUTHIAH S, Polubothu S, Husain A, Oliphant T, et al
    A mosaic variant in MAP2K1 is associated with giant naevus-spilus type congenital melanocytic naevus and melanoma development.
    Br J Dermatol. 2020 Apr 9. doi: 10.1111/bjd.19118.
    PubMed     Abstract available


  10. CUST AE
    Gene-environment interactions and melanoma risk.
    Br J Dermatol. 2020 Apr 1. doi: 10.1111/bjd.18986.
    PubMed    


  11. THOMPSON AR, Cockayne S
    It's the worry that got him in the end: the importance in treating melanoma holistically and dealing with fear of recurrence.
    Br J Dermatol. 2020;182:821-822.
    PubMed    


    March 2020
  12. FREDEAU L, Bohelay G, Shourick J, Piver D, et al
    Paraneoplastic neutrophilic leukemoid reaction in a melanoma patient: association between tumour volume and leukocytosis.
    Br J Dermatol. 2020 Mar 30. doi: 10.1111/bjd.19059.
    PubMed     Abstract available


  13. OLAMIJU B, Leventhal JS
    Near total body vitiligo secondary to immunotherapy for metastatic melanoma.
    Br J Dermatol. 2020 Mar 9. doi: 10.1111/bjd.18944.
    PubMed    


  14. VON SCHUCKMANN LA, Khosrotehrani K, Ghiasvand R, Hughes MCB, et al
    Statins may reduce disease recurrence in patients with ulcerated primary melanoma.
    Br J Dermatol. 2020 Mar 4. doi: 10.1111/bjd.19012.
    PubMed     Abstract available


  15. ISAKSSON K, Mikiver R, Eriksson H, Lapins J, et al
    Survival in 31 670 patients with thin melanomas - a Swedish population-based study.
    Br J Dermatol. 2020 Mar 4. doi: 10.1111/bjd.19015.
    PubMed     Abstract available


  16. YANG DD, Salciccioli JD, Marshall DC, Sheri A, et al
    Trends in malignant melanoma mortality in 31 countries from 1985 to 2015.
    Br J Dermatol. 2020 Mar 4. doi: 10.1111/bjd.19010.
    PubMed     Abstract available


  17. WONG AYS, Froslev T, Dearing L, Forbes HJ, et al
    The association between partner bereavement and melanoma: cohort studies in the U.K. and Denmark.
    Br J Dermatol. 2020 Mar 3. doi: 10.1111/bjd.18889.
    PubMed     Abstract available


    February 2020
  18. CHI CC
    Dermoscopy and reflectance confocal microscopy for early diagnosis of amelanotic/hypomelanotic melanoma: still a long way to go?
    Br J Dermatol. 2020 Feb 23. doi: 10.1111/bjd.18893.
    PubMed    


  19. LIVINGSTONE E, Zaremba A, Horn S, Ugurel S, et al
    GNAQ and GNA11 mutant non-uveal melanoma, a subtype distinct from both cutaneous and uveal melanoma.
    Br J Dermatol. 2020 Feb 16. doi: 10.1111/bjd.18947.
    PubMed     Abstract available


  20. FILONI A, Lospalluti L, Zanframundo G, De Marco A, et al
    Light brown structureless areas as predictor of melanoma in situ.
    Br J Dermatol. 2020 Feb 4. doi: 10.1111/bjd.18926.
    PubMed     Abstract available


  21. CUST AE
    Who dies from thin melanoma?
    Br J Dermatol. 2020 Feb 3. doi: 10.1111/bjd.18871.
    PubMed    


    January 2020
  22. BUJA A, Rivera M, De Polo A, Zorzi M, et al
    Real-world data for direct stage-specific costs of melanoma healthcare.
    Br J Dermatol. 2020 Jan 29. doi: 10.1111/bjd.18896.
    PubMed     Abstract available


  23. POLESIE S, Gillstedt M, Paoli J, Osmancevic A, et al
    Methotrexate treatment for psoriasis patients and risk of cutaneous melanoma: a nested case-control study.
    Br J Dermatol. 2020 Jan 25. doi: 10.1111/bjd.18887.
    PubMed     Abstract available


  24. WARD SV, Gibbs DC, Orlow I, Thomas NE, et al
    Association of IRF4 SNP rs12203592 with melanoma-specific survival.
    Br J Dermatol. 2020 Jan 20. doi: 10.1111/bjd.18881.
    PubMed     Abstract available


  25. DAI W, Liu H, Liu Y, Xu X, et al
    Genetic variants in the folate metabolic pathway genes predict melanoma-specific survival.
    Br J Dermatol. 2020 Jan 18. doi: 10.1111/bjd.18878.
    PubMed     Abstract available


  26. CRAIG S, Viros A
    New biomarkers improve stratification of patients with melanoma.
    Br J Dermatol. 2020;182:5-6.
    PubMed    


    December 2019
  27. THOMPSON JF, Friedman EB
    The intriguing association between smoking and reduced melanoma risk.
    Br J Dermatol. 2019 Dec 23. doi: 10.1111/bjd.18728.
    PubMed    


  28. DOCAMPO-SIMON A, Sanchez-Pujol MJ, Belinchon-Romero I, Niveiro M, et al
    Image Gallery: Haematogenous metastasis of melanoma mimicking lymphangioma.
    Br J Dermatol. 2019 Dec 17. doi: 10.1111/bjd.18723.
    PubMed    


  29. BETZ-STABLEIN B, Koh U, Plasmeijer E, Janda M, et al
    Self-reported naevus density may lead to misclassification of melanoma risk.
    Br J Dermatol. 2019 Dec 12. doi: 10.1111/bjd.18802.
    PubMed     Abstract available


  30. MCMENIMAN EK, Duffy DL, Jagirdar K, Lee KJ, et al
    The interplay of sun-damage and genetic risk in Australian multiple and single primary melanoma cases and controls.
    Br J Dermatol. 2019 Dec 3. doi: 10.1111/bjd.18777.
    PubMed     Abstract available


    November 2019
  31. BELL KJL
    Causal inference in melanoma epidemiology using Mendelian randomization.
    Br J Dermatol. 2019 Nov 28. doi: 10.1111/bjd.18646.
    PubMed    


  32. ROBINSON JK
    Frequency of 'regular' skin checks by dermatologists for melanoma survivors.
    Br J Dermatol. 2019 Nov 27. doi: 10.1111/bjd.18626.
    PubMed    


  33. WEBER J, Glutsch V, Geissinger E, Haug L, et al
    Neoadjuvant Immunotherapy with combined Ipilimumab and Nivolumab in Melanoma Patients with Primary or In-transit Disease.
    Br J Dermatol. 2019 Nov 26. doi: 10.1111/bjd.18739.
    PubMed     Abstract available


  34. OLSEN CM, Pandeya N, Law MH, MacGregor S, et al
    Does polygenic risk influence associations between sun exposure and melanoma?: a prospective cohort analysis.
    Br J Dermatol. 2019 Nov 20. doi: 10.1111/bjd.18703.
    PubMed     Abstract available


  35. LAN J, Wen J, Cao S, Yin T, et al
    The diagnostic accuracy of dermoscopy and reflectance confocal microscopy for amelanotic/hypomelanotic melanoma: a systematic review and meta-analysis.
    Br J Dermatol. 2019 Nov 20. doi: 10.1111/bjd.18722.
    PubMed     Abstract available


  36. FUJIMURA T, Tanita K, Sato Y, Lyu C, et al
    Immune checkpoint inhibitor-induced vitiligo in advanced melanoma could be related to increased levels of CCL19.
    Br J Dermatol. 2019 Nov 20. doi: 10.1111/bjd.18721.
    PubMed     Abstract available


  37. JOHANSSON P
    Differences between acral and nonacral melanoma genomes.
    Br J Dermatol. 2019 Nov 19. doi: 10.1111/bjd.18615.
    PubMed    


  38. DEL REGNO L, Louveau B, Battistella M, Sadoux A, et al
    Clinical significance of BRAF/NRAS concurrent mutations in a clinic-based metastatic melanoma cohort.
    Br J Dermatol. 2019 Nov 1. doi: 10.1111/bjd.18641.
    PubMed     Abstract available


  39. DUFFY DL, Lee KJ, Jagirdar K, Pflugfelder A, et al
    Naevus count and MC1R R alleles contribute to melanoma risk.
    Br J Dermatol. 2019;181:e119-e142.
    PubMed     Abstract available


    October 2019
  40. AGUILAR JA, Irurzun AL, Bayona JIY, Rodriguez MA, et al
    Image Gallery: Zosteriform metastasis from melanoma.
    Br J Dermatol. 2019 Oct 30. doi: 10.1111/bjd.18567.
    PubMed    


  41. HOWARD M, Xie C, Wee E, Wolfe R, et al
    Acral lentiginous melanoma: differences in survival compared to other subtypes.
    Br J Dermatol. 2019 Oct 19. doi: 10.1111/bjd.18620.
    PubMed     Abstract available


  42. TOLAND AE
    Developing risk prediction models for melanoma: balancing better predictive value with ease of clinical implementation.
    Br J Dermatol. 2019 Oct 13. doi: 10.1111/bjd.18531.
    PubMed    


  43. DEINLEIN T, Longo C, Schulter G, Pizzichetta MA, et al
    The prevailing dermoscopic vascular pattern in melanoma is influenced by tumor thickness and pigmentation type.
    Br J Dermatol. 2019 Oct 12. doi: 10.1111/bjd.18610.
    PubMed     Abstract available


    September 2019
  44. CLAESON M, Baade P, Brown S, Soyer HP, et al
    Clinicopathological factors associated with death from thin (</=1.00mm) melanoma.
    Br J Dermatol. 2019 Sep 28. doi: 10.1111/bjd.18560.
    PubMed     Abstract available


  45. KOSTAKI M, Plaka M, Stergiopoulou A, Kypreou K, et al
    Trends in epidemiology of melanoma in situ in Greece: Data from a melanoma reference center during the period 2000-2018.
    Br J Dermatol. 2019 Sep 23. doi: 10.1111/bjd.18551.
    PubMed     Abstract available


  46. GIBSON JAG, Dobbs TD, Griffiths R, Song J, et al
    The Association of Smoking and Socioeconomic status on Cutaneous Melanoma: a population based, data linkage, case-control study.
    Br J Dermatol. 2019 Sep 17. doi: 10.1111/bjd.18526.
    PubMed     Abstract available


  47. CUST AE, Badcock C, Smith J, Thomas NE, et al
    A risk prediction model for development of subsequent primary melanoma in a population-based cohort.
    Br J Dermatol. 2019 Sep 14. doi: 10.1111/bjd.18524.
    PubMed     Abstract available


  48. BAILEY EE, Mayer JE, Geller AC, Johnson TM, et al
    Role of the partner/spouse in melanoma discovery and related health behaviors and practices.
    Br J Dermatol. 2019 Sep 5. doi: 10.1111/bjd.18478.
    PubMed     Abstract available


  49. STILLER HT, Mikiver R, Uppugunduri S, Lindholm C, et al
    Health Related Quality of Life in Melanoma Patients - characterization of a Swedish cohort.
    Br J Dermatol. 2019 Sep 5. doi: 10.1111/bjd.18486.
    PubMed     Abstract available


    August 2019
  50. GOLDINGER SM, Valeska Matter A, Urner-Bloch U, Narainsing J, et al
    Binimetinib in heavily pretreated NRAS-mutant Melanoma Patients with Brain Metastases.
    Br J Dermatol. 2019 Aug 22. doi: 10.1111/bjd.18449.
    PubMed     Abstract available


  51. SHEEN YS, Tan KT, Tse KP, Liao YH, et al
    Genetic Alterations in Primary Melanoma in Taiwan.
    Br J Dermatol. 2019 Aug 13. doi: 10.1111/bjd.18425.
    PubMed     Abstract available


  52. FEARFIELD L, Nobbs J, Petruckevitch A, Harland C, et al
    Severe vitamin D deficiency associated with BRAF mutated melanoma.
    Br J Dermatol. 2019 Aug 5. doi: 10.1111/bjd.18413.
    PubMed     Abstract available


  53. VUONG K, Armstrong BK, Drummond M, Hopper JL, et al
    Development and external validation study of a melanoma risk prediction model incorporating clinically-assessed naevi and solar lentigines.
    Br J Dermatol. 2019 Aug 4. doi: 10.1111/bjd.18411.
    PubMed     Abstract available


    July 2019
  54. GAMBICHLER T, Schroter U, Hoxtermann S, Susok L, et al
    Decline of PD-1 positive circulating T regulatory cells predicting more favorable clinical outcome of melanoma patients under immune checkpoint blockade.
    Br J Dermatol. 2019 Jul 30. doi: 10.1111/bjd.18379.
    PubMed     Abstract available


  55. RIBERO S
    Synergy between MC1R mutations and a high naevus count in increasing melanoma risk in the general population.
    Br J Dermatol. 2019 Jul 28. doi: 10.1111/bjd.18301.
    PubMed    


  56. GAMBICHLER T, Susok L, Fels M, Schneider-Gold C, et al
    Autoimmune radiculoplexus neuropathy under adjuvant nivolumab treatment of a female melanoma patient.
    Br J Dermatol. 2019 Jul 19. doi: 10.1111/bjd.18358.
    PubMed     Abstract available


  57. OLSEN CM
    Reproductive factors and risk of melanoma: still unresolved.
    Br J Dermatol. 2019 Jul 9. doi: 10.1111/bjd.18136.
    PubMed    


  58. ARMSTRONG J
    Bioenergetic cellular index: a clinical biomarker to identify metabolic adaption in melanoma?
    Br J Dermatol. 2019;181:15-16.
    PubMed    


  59. FRANKE V
    Talimogene laherparepvec monotherapy, an elegant alternative to systemic immunotherapy for the treatment of early metastatic melanoma.
    Br J Dermatol. 2019;181:20-21.
    PubMed    


  60. TOLAND AE
    POT1 pathogenic variants: not all telomere pathway genes are equal in risk of hereditary cutaneous melanoma.
    Br J Dermatol. 2019;181:14-15.
    PubMed    


    June 2019
  61. KIM HS, Kim HJ, Hong ES, Kim KB, et al
    The incidence and survival of melanoma and nonmelanoma skin cancer in patients with vitiligo: a nationwide population-based matched cohort study in Korea.
    Br J Dermatol. 2019 Jun 24. doi: 10.1111/bjd.18247.
    PubMed     Abstract available


  62. LIYANAGE UE, Law MH, Barrett JH, Iles MM, et al
    Is there a causal relationship between vitamin D and melanoma risk? : A Mendelian randomization study.
    Br J Dermatol. 2019 Jun 19. doi: 10.1111/bjd.18238.
    PubMed     Abstract available


  63. MCINERNEY-LEO AM, Finnane A
    The personal touch: does the communication method affect response to melanoma genetic risk?
    Br J Dermatol. 2019;180:1288-1289.
    PubMed    


    May 2019
  64. CALBET-LLOPART N, Potrony M, Tell-Marti G, Carrera C, et al
    Detection of cell-free circulating BRAF(V) (600E) by droplet digital PCR in melanoma and non-melanoma patients under dermatological surveillance.
    Br J Dermatol. 2019 May 18. doi: 10.1111/bjd.18147.
    PubMed     Abstract available


  65. RUSSELL-JONES R
    A Brighter Future for Melanoma.
    Br J Dermatol. 2019 May 11. doi: 10.1111/bjd.18122.
    PubMed     Abstract available


  66. KIM TH, Kim HJ, Seo JW, Song KH, et al
    Efficacy and clinical significance of omitting blue dye injection during sentinel lymph node biopsy before Mohs micrographic surgery for malignant melanoma of the lower extremities.
    Br J Dermatol. 2019 May 11. doi: 10.1111/bjd.18121.
    PubMed     Abstract available


  67. ELLIS R, Tang D, Nasr B, Greenwood A, et al
    Epidermal AMBRA1 and Loricrin; a paradigm shift in the prognostication and stratification of AJCC stage I melanomas.
    Br J Dermatol. 2019 May 6. doi: 10.1111/bjd.18086.
    PubMed     Abstract available


  68. VENTURA A, Pitocco R, Di Stefani A, Cota C, et al
    Image Gallery: Peculiar subungual localization of a second primary melanoma during BRAF inhibitors treatment for metastatic melanoma: case report.
    Br J Dermatol. 2019;180:e142.
    PubMed    


    April 2019
  69. ELEN-LIRA F, Podlipnik S, Potrony M, Tell-Marti G, et al
    Inherited MC1R variants in melanoma patients are associated with better survival in females.
    Br J Dermatol. 2019 Apr 23. doi: 10.1111/bjd.18024.
    PubMed     Abstract available


  70. GASPARINI G, Madjlessi N, Delyon J, Carmisciano L, et al
    Usefulness of the "two-step method" of digital follow-up in early stage melanoma detection in at high risk French patients - A retrospective 4-year study.
    Br J Dermatol. 2019 Apr 12. doi: 10.1111/bjd.18006.
    PubMed     Abstract available


  71. DIENG M, Morton RL, Costa DSJ, Butow PN, et al
    Benefits of a brief psychological intervention targeting fear of cancer recurrence in people at high risk of developing another melanoma: 12-month follow-up results of a randomised controlled trial.
    Br J Dermatol. 2019 Apr 9. doi: 10.1111/bjd.17990.
    PubMed     Abstract available


  72. SCARFI F, Gori A, Topa A, Trane L, et al
    Image Gallery: In vivo fluorescence-advanced videodermatoscopy for the characterization of skin melanocytic pigmented lesions.
    Br J Dermatol. 2019;180:e104.
    PubMed    


    March 2019
  73. ELIAS ML, Lambert WC
    Surgical Management of Localized Melanoma: A National Cancer Database Retrospective Review.
    Br J Dermatol. 2019 Mar 25. doi: 10.1111/bjd.17901.
    PubMed     Abstract available


  74. DUFFY DL, Lee KJ, Jagirdar K, Pflugfelder A, et al
    High naevus count and MC1R red hair alleles contribute synergistically to increased melanoma risk.
    Br J Dermatol. 2019 Mar 1. doi: 10.1111/bjd.17833.
    PubMed     Abstract available


    February 2019
  75. RESSLER J, Silmbrod R, Stepan A, Tuchmann F, et al
    T-VEC in advanced Melanoma - Complete response in a heart and kidney transplant patient: A case report.
    Br J Dermatol. 2019 Feb 18. doi: 10.1111/bjd.17783.
    PubMed     Abstract available


  76. STOER NC, Botteri E, Ghiasvand R, Busund M, et al
    Reproductive factors and risk of melanoma: a population-based cohort study.
    Br J Dermatol. 2019 Feb 12. doi: 10.1111/bjd.17771.
    PubMed     Abstract available


  77. HALK AB, Potjer TP, Kukutsch NA, Vasen HFA, et al
    Surveillance for familial melanoma: recommendations from a national centre of expertise.
    Br J Dermatol. 2019 Feb 11. doi: 10.1111/bjd.17767.
    PubMed     Abstract available


  78. ZOUTENDIJK J, Tio D, Koljenovic S, van den Bos RR, et al
    Nine percent of biopsy proven lentigo maligna are reclassified as lentigo maligna melanoma after surgery.
    Br J Dermatol. 2019 Feb 4. doi: 10.1111/bjd.17714.
    PubMed     Abstract available


  79. CHAN MP
    Refining the ever-evolving molecular landscape of spitzoid melanocytic neoplasms.
    Br J Dermatol. 2019;180:262.
    PubMed    


    January 2019
  80. JIYAD Z, Akhras V
    Incidence of melanoma and outcomes of longitudinal melanonychia in a cohort of cases referred to a London dermatology department.
    Br J Dermatol. 2019 Jan 4. doi: 10.1111/bjd.17607.
    PubMed     Abstract available


  81. SCHILLING B, Wiesner T
    Tackling melanoma by adjuvant therapy: why, whom and how?
    Br J Dermatol. 2019;180:1-2.
    PubMed    


  82. VAN AKKOOI ACJ, Hayes A
    Recent developments in lymph node surgery for melanoma.
    Br J Dermatol. 2019;180:5-7.
    PubMed    


  83. UZUNCAKMAK TK, Akay BN, Ozkanli S
    Different dermoscopic features of clonal seborrhoeic keratoses.
    Br J Dermatol. 2019;180:197-198.
    PubMed    


    December 2018
  84. MIURA K, Olsen CM, Rea S, Marsden J, et al
    Do airline pilots and cabin crew have raised risks of melanoma and other skin cancers? Systematic review and meta-analysis.
    Br J Dermatol. 2018 Dec 26. doi: 10.1111/bjd.17586.
    PubMed     Abstract available


  85. FENTON GL, Smit AK, Keogh L, Cust AE, et al
    Exploring the Emotional and Behavioural Reactions to Receiving Personalised Melanoma Genomic Risk Information: A Qualitative Study.
    Br J Dermatol. 2018 Dec 22. doi: 10.1111/bjd.17582.
    PubMed     Abstract available


  86. NAJERA L, Alonso-Juarranz M, Garrido M, Ballestin C, et al
    Prognostic implications of markers of the metabolic phenotype in human cutaneous melanoma.
    Br J Dermatol. 2018 Dec 7. doi: 10.1111/bjd.17513.
    PubMed     Abstract available


  87. FOX JA, Langbecker D, Rosenberg J, Ekberg S, et al
    Uncertain diagnosis and prognosis in advanced melanoma: A qualitative study of the experiences of bereaved carers in a time of immune and targeted therapies.
    Br J Dermatol. 2018 Dec 4. doi: 10.1111/bjd.17511.
    PubMed     Abstract available


    November 2018
  88. CORRIE PG, Terheyden P, Ten Tije AJ, Herbst R, et al
    A prospective, observational safety study of patients with BRAF(V) (600) -mutated unresectable or metastatic melanoma treated with vemurafenib [Zelboraf Safety Study (ZeSS)].
    Br J Dermatol. 2018 Nov 29. doi: 10.1111/bjd.17465.
    PubMed     Abstract available


  89. POTRONY M, Puig-Butille JA, Ribera-Sola M, Iyer V, et al
    POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families.
    Br J Dermatol. 2018 Nov 19. doi: 10.1111/bjd.17443.
    PubMed     Abstract available


  90. MAEDA T, Yoshino K, Nagai K, Oaku S, et al
    Efficacy of nivolumab monotherapy against acral lentiginous melanoma and mucosal melanoma in Asian patients.
    Br J Dermatol. 2018 Nov 17. doi: 10.1111/bjd.17434.
    PubMed     Abstract available


  91. OKIYAMA N, Inoue S, Saito A, Nakamura Y, et al
    Antihelix/helix violaceous macules in Japanese patients with anti-melanoma differentiation-associated protein 5 (MDA5) antibody-associated dermatomyositis.
    Br J Dermatol. 2018 Nov 15. doi: 10.1111/bjd.17431.
    PubMed     Abstract available


  92. VERAITCH O, Lewis F, Craythorne E, Calonje E, et al
    Management of vulval melanoma in situ with imiquimod.
    Br J Dermatol. 2018 Nov 15. doi: 10.1111/bjd.17433.
    PubMed     Abstract available


    October 2018
  93. VERYKIOU S, Alexander M, Edwards N, Plummer R, et al
    Harnessing autophagy to overcome MEK-inhibitor induced resistance in metastatic melanoma.
    Br J Dermatol. 2018 Oct 19. doi: 10.1111/bjd.17333.
    PubMed     Abstract available


    September 2018
  94. KOREKAWA A, Akasaka E, Rokunohe D, Fukui T, et al
    Nagashima-type palmoplantar keratoderma and malignant melanoma in Japanese patients.
    Br J Dermatol. 2018 Sep 26. doi: 10.1111/bjd.17251.
    PubMed     Abstract available


  95. ROGIERS A, Thomas D, Vander Borght S, van den Oord JJ, et al
    Dabrafenib plus trametinib in BRAF K601E-mutant melanoma.
    Br J Dermatol. 2018 Sep 24. doi: 10.1111/bjd.17250.
    PubMed     Abstract available


  96. XU S, Stump TK, Jain J, Alshurafa N, et al
    Variation in daily ultraviolet light exposure and sun protection behaviours of melanoma survivors: an observational single-arm pilot study with a wearable sensor.
    Br J Dermatol. 2018 Sep 12. doi: 10.1111/bjd.17196.
    PubMed     Abstract available


  97. BRANCACCIO G, Napolitano S, Troiani T, Franco R, et al
    Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC?
    Br J Dermatol. 2018 Sep 5. doi: 10.1111/bjd.17145.
    PubMed     Abstract available


  98. MATTHEWS NH, Risica PM, Ferris LK, Beatson M, et al
    Psychosocial impact of skin biopsies in the setting of melanoma screening - A cross-sectional survey.
    Br J Dermatol. 2018 Sep 5. doi: 10.1111/bjd.17134.
    PubMed     Abstract available


    August 2018
  99. FOGARTY GB, McLaren KR, Moutrie Z, Poon TSC, et al
    Locally advanced skin cancers of the frail and elderly - consider adaptive split course radiotherapy (ASCRT).
    Br J Dermatol. 2018 Aug 16. doi: 10.1111/bjd.17037.
    PubMed     Abstract available


  100. CUST AE, Aitken J, Baade P, Whiteman D, et al
    Why a randomised melanoma screening trial may be a good idea.
    Br J Dermatol. 2018 Aug 13. doi: 10.1111/bjd.17089.
    PubMed     Abstract available


  101. VAN DOORN R
    Methylation marks melanoma metastasis.
    Br J Dermatol. 2018;179:250-251.
    PubMed    


    June 2018
  102. KEOHANE SG, Proby CM, Newlands C, Motley RJ, et al
    The new 8th edition of TNM staging and its implications for skin cancer: a review by the British Association of Dermatologists and the Royal College of Pathologists, United Kingdom.
    Br J Dermatol. 2018 Jun 19. doi: 10.1111/bjd.16892.
    PubMed     Abstract available


  103. FARAH M, Nagarajan P, Curry JL, Tang Z, et al
    Spitzoid melanoma with histopathologic features of ALK gene rearrangement exhibiting ALK copy number gain: A novel mechanism of ALK activation in spitzoid neoplasia.
    Br J Dermatol. 2018 Jun 13. doi: 10.1111/bjd.16881.
    PubMed     Abstract available


  104. HALVORSEN JA, Loberg M, Gjersvik P, Roscher I, et al
    Why a randomized melanoma screening trial is not a good idea.
    Br J Dermatol. 2018 Jun 12. doi: 10.1111/bjd.16784.
    PubMed    


  105. PODLIPNIK S, Moreno-Ramirez D, Carrera C, Barreiro A, et al
    Cost-effectiveness analysis of imaging strategy for an intensive follow-up of patients with AJCC stage IIB, IIC and III malignant melanoma.
    Br J Dermatol. 2018 Jun 7. doi: 10.1111/bjd.16833.
    PubMed     Abstract available


  106. STENEHJEM JS, Veierod MB, Nilsen LT, Ghiasvand R, et al
    Anthropometric factors and Breslow thickness: Prospective data on 2570 cutaneous melanoma cases in the population-based Janus Cohort.
    Br J Dermatol. 2018 Jun 1. doi: 10.1111/bjd.16825.
    PubMed     Abstract available


    May 2018
  107. WAN MT, Ming ME
    Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal.
    Br J Dermatol. 2018 May 15. doi: 10.1111/bjd.16785.
    PubMed     Abstract available


  108. CAYUELA A, Cayuela L, Rodriguez-Dominguez S, Lorente AI, et al
    Is melanoma mortality declining in Spain? Analysis of trends 1975-2016.
    Br J Dermatol. 2018 May 14. doi: 10.1111/bjd.16777.
    PubMed     Abstract available


  109. FUJISAWA Y
    Baseline neutrophil-to-lymphocyte ratio in patients with advanced melanoma treated with immune checkpoint inhibitors: reply from the authors.
    Br J Dermatol. 2018 May 7. doi: 10.1111/bjd.16689.
    PubMed    


  110. KRAEMER KH, Tamura D, Khan SG
    Pembrolizumab treatment of a patient with xeroderma pigmentosum with disseminated melanoma and multiple nonmelanoma skin cancers.
    Br J Dermatol. 2018;178:1009.
    PubMed    


    April 2018
  111. RAUWERDINK DJW, Roach REJ, Etty M, Kukutsch NA, et al
    Melanoma diagnosis during periodic surveillance of patients with multiple atypical naevi.
    Br J Dermatol. 2018 Apr 28. doi: 10.1111/bjd.16708.
    PubMed     Abstract available


  112. BAN L, Labbouz S, Grindlay D, Batchelor J, et al
    Risk of skin cancer in people with vitiligo: a systematic review and meta-analysis.
    Br J Dermatol. 2018 Apr 28. doi: 10.1111/bjd.16703.
    PubMed     Abstract available


  113. LANGAN EA, Gratz V, Billmann F, Zillikens D, et al
    Does the gastrointestinal microbiome contribute to the "obesity paradox" in melanoma survival?
    Br J Dermatol. 2018 Apr 16. doi: 10.1111/bjd.16681.
    PubMed     Abstract available


  114. KIM J, Kim YH, Park B, Seo HM, et al
    Multispectral ex vivo photoacoustic imaging of cutaneous melanoma for better selection of the excision margin.
    Br J Dermatol. 2018 Apr 16. doi: 10.1111/bjd.16677.
    PubMed     Abstract available


  115. MACHET L, Zaragoza J, Finon A, Garnier M, et al
    Baseline neutrophil to lymphocyte ratio in patients with advanced melanoma treated with immune check point inhibitors.
    Br J Dermatol. 2018 Apr 16. doi: 10.1111/bjd.16675.
    PubMed     Abstract available


  116. HAAS L, Wiesner T, Obenauf AC
    A new era of proactive melanoma therapy: hit hard, hit early.
    Br J Dermatol. 2018;178:817-820.
    PubMed    


    March 2018
  117. VU M, Adler NR, Wee E, Wolfe R, et al
    Impact of naevus association on survival for nodular and superficial spreading melanomas.
    Br J Dermatol. 2018 Mar 24. doi: 10.1111/bjd.16556.
    PubMed     Abstract available


  118. FORSCHNER A, Keim U, Hofmann M, Spankuch I, et al
    Diagnostic accuracy of dermatofluoroscopy in cutaneous melanoma detection: Results of a prospective multicentre clinical study in 476 pigmented lesions.
    Br J Dermatol. 2018 Mar 22. doi: 10.1111/bjd.16565.
    PubMed     Abstract available


  119. MARCHAND A, Tallet A, Collin C, Cormier B, et al
    A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma.
    Br J Dermatol. 2018 Mar 1. doi: 10.1111/bjd.16499.
    PubMed     Abstract available


  120. BARRAGAN-ESTUDILLO ZF, Jesus-Silva MA, Chavez-Bourgeois MM, Brito J, et al
    Image Gallery: Transition pattern in acral melanoma.
    Br J Dermatol. 2018;178:e225.
    PubMed    


    February 2018
  121. LONGO C, Lallas A, Kyrgidis A, Bassoli S, et al
    Wide skin markings pattern - melanoma descriptor or patient-related factor?: reply from authors.
    Br J Dermatol. 2018 Feb 7. doi: 10.1111/bjd.16430.
    PubMed     Abstract available


  122. RISHPON A, Marchetti M, Marghoob A
    Wide skin markings pattern - melanoma descriptor or patient-related factor?
    Br J Dermatol. 2018 Feb 6. doi: 10.1111/bjd.16420.
    PubMed     Abstract available


  123. FUJISAWA Y, Yoshino K, Otsuka A, Funakoshi T, et al
    Baseline neutrophil to lymphocyte ratio combined with serum LDH level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population.
    Br J Dermatol. 2018 Feb 6. doi: 10.1111/bjd.16427.
    PubMed     Abstract available


  124. DANDO EE, Lim GFS, Ho J, James A, et al
    Image Gallery: Pigmented mammary Paget disease: a rare clinicopathological variant mimicking melanoma.
    Br J Dermatol. 2018;178:e143.
    PubMed    


  125. CUST AE
    Prognostic features for acral lentiginous melanoma.
    Br J Dermatol. 2018;178:311-312.
    PubMed    


  126. BELL KJL, Cust AE
    Beyond country-specific incidence and mortality: the global burden of melanoma.
    Br J Dermatol. 2018;178:315-316.
    PubMed    


    January 2018
  127. BORSARI S, Pampena R, Benati E, Bombonato C, et al
    In vivo dermoscopic and confocal microscopy multi-step algorithm to detect in situ melanomas.
    Br J Dermatol. 2018 Jan 21. doi: 10.1111/bjd.16364.
    PubMed     Abstract available


  128. LAINO AM, Berry EG, Jagirdar K, Lee KJ, et al
    Iris pigmented lesions as a marker of cutaneous melanoma risk: an Australian case-control study.
    Br J Dermatol. 2018 Jan 8. doi: 10.1111/bjd.16323.
    PubMed     Abstract available


  129. VERYKIOU S, Edwards N, Hill D
    How breakthroughs in translational research have impacted treatment strategies for melanoma.
    Br J Dermatol. 2018;178:5-8.
    PubMed    


  130. MUTHIAH S, Tang D, Nasr B, Verykiou S, et al
    A new era in holistic care: bridging the gap between dermatologists and oncologists for the treatment of malignant melanoma.
    Br J Dermatol. 2018;178:1-4.
    PubMed    


  131. WIESNER T, Zbyszewski A
    Progress in the diagnosis and therapy of melanoma.
    Br J Dermatol. 2018;178:12-14.
    PubMed    


  132. WEHNER MR
    Sunscreen and melanoma prevention: evidence and expectations.
    Br J Dermatol. 2018;178:15-16.
    PubMed    


  133. HWANG SJE, Fernandez-Penas P
    Pigmentary evolution with pembrolizumab use.
    Br J Dermatol. 2018;178:32-33.
    PubMed    


    December 2017
  134. MCINERNEY-LEO AM, Wheeler L, Sturm RA, Tan JM, et al
    Point mutation in p14(ARF) -specific exon 1beta of CDKN2A causing familial melanoma and astrocytoma.
    Br J Dermatol. 2017 Dec 26. doi: 10.1111/bjd.16275.
    PubMed     Abstract available


  135. DE UNAMUNO BUSTOS B, Murria Estal R, Perez Simo G, Simarro Farinos J, et al
    Aberrant DNA methylation is associated with aggressive clinicopathological features and poor survival in cutaneous melanoma.
    Br J Dermatol. 2017 Dec 26. doi: 10.1111/bjd.16254.
    PubMed     Abstract available


  136. SALOMON G, Maza A, Boulinguez S, Paul C, et al
    Efficacy of anti-PD-1 on skin carcinomas and melanoma metastases in an Xeroderma Pigmentosum patient.
    Br J Dermatol. 2017 Dec 23. doi: 10.1111/bjd.16270.
    PubMed     Abstract available


  137. OLSEN CM, Wilson LF, Green AC, Biswas N, et al
    How many melanomas might be prevented if more people applied sunscreen regularly?
    Br J Dermatol. 2017 Dec 14. doi: 10.1111/bjd.16079.
    PubMed     Abstract available


    November 2017
  138. WINSLOW UC, Nordestgaard BG, Afzal S
    High plasma 25-hydroxyvitamin D and high risk of non-melanoma skin cancer: a Mendelian randomisation study of 97849 individuals.
    Br J Dermatol. 2017 Nov 16. doi: 10.1111/bjd.16127.
    PubMed     Abstract available


  139. DEL PUERTO C, Navarrete-Dechent C, Molgo M, Camargo CA Jr, et al
    Immunohistochemical expression of vitamin D receptor in melanocytic nevi and cutaneous melanoma. A case-control study.
    Br J Dermatol. 2017 Nov 6. doi: 10.1111/bjd.16103.
    PubMed     Abstract available


    October 2017
  140. TRAN AD, Fogarty G, Nowak AK, Espinoza D, et al
    A systematic review and meta-analysis of utility estimates in melanoma.
    Br J Dermatol. 2017 Oct 27. doi: 10.1111/bjd.16098.
    PubMed     Abstract available


  141. SEO JW, Ha SM, Song KH
    Insulin-Like Growth Factor-II mRNA-Binding Protein 3 as a Novel Prognostic Biomarker for Acral Lentiginous Melanoma.
    Br J Dermatol. 2017 Oct 19. doi: 10.1111/bjd.16077.
    PubMed     Abstract available


  142. BASSOLI S, Kyrgidis A, Ciardo S, Casari A, et al
    Uncovering the diagnostic dermoscopic features of flat melanomas located on the lower limbs.
    Br J Dermatol. 2017 Oct 7. doi: 10.1111/bjd.16030.
    PubMed     Abstract available


  143. SCHAIDER H, Sturm RA
    The evolving universe of BRAF mutations in melanoma.
    Br J Dermatol. 2017;177:893.
    PubMed    


  144. ROBINSON JK, Spring B
    Personalized melanoma genomic risk information:perception of shared risk initiates sharing with family.
    Br J Dermatol. 2017;177:890-891.
    PubMed    


    September 2017
  145. SATTLER EC, Ertl-Wagner B, Pellegrini C, Peris K, et al
    Cutaneous melanoma in Birt-Hogg-Dube syndrome - part of the clinical spectrum?
    Br J Dermatol. 2017 Sep 4. doi: 10.1111/bjd.15937.
    PubMed     Abstract available


  146. ZNAOR A
    Melanoma burden, healthcare utilization and the potential for overdiagnosis in the elderly U.S. population.
    Br J Dermatol. 2017;177:625.
    PubMed    


    August 2017
  147. YOULDEN DR, Baade PD, Aitken JF, Green AC, et al
    Prognostic importance of a second invasive primary melanoma according to tumor stage.
    Br J Dermatol. 2017 Aug 3. doi: 10.1111/bjd.15863.
    PubMed     Abstract available


  148. BERK-KRAUSS J, Stein JA
    The role of access to care in acral lentiginous melanoma survival.
    Br J Dermatol. 2017;177:341-342.
    PubMed    


  149. HILL D, Lovat P
    Cover Image: Invasion of a cutaneous melanoma tumour.
    Br J Dermatol. 2017;177:599.
    PubMed    


    July 2017
  150. ADLER NR, Kelly JW, Haydon A, McLean CA, et al
    Clinicopathological characteristics and prognosis of patients with multiple primary melanomas.
    Br J Dermatol. 2017 Jul 28. doi: 10.1111/bjd.15855.
    PubMed     Abstract available


  151. DIAS-SANTAGATA D, Selim MA, Su Y, Peng Y, et al
    KIT Mutations and CD117 Overexpression Are Markers of Better Progression-Free Survival in Vulvar Melanomas.
    Br J Dermatol. 2017 Jul 22. doi: 10.1111/bjd.15836.
    PubMed     Abstract available


  152. TERAMOTO Y, Keim U, Gesierich A, Schuler G, et al
    Acral lentiginous melanoma - a skin cancer with unfavourable prognostic features. A study of the German Central Malignant Melanoma Registry (CMMR) in 2050 patients.
    Br J Dermatol. 2017 Jul 14. doi: 10.1111/bjd.15803.
    PubMed     Abstract available


  153. GIBBS DC, Ward SV, Orlow I, Cadby G, et al
    Functional melanoma-risk variant IRF4 rs12203592 associated with Breslow thickness: a pooled international study of primary melanomas.
    Br J Dermatol. 2017 Jul 1. doi: 10.1111/bjd.15784.
    PubMed     Abstract available


  154. MAHER NG, Guitera P
    Imiquimod treatment for lentigo maligna: LIMIT-1 trial.
    Br J Dermatol. 2017;177:324-325.
    PubMed    


    June 2017
  155. SMIT AK, Keogh LA, Newson AJ, Butow PN, et al
    Does personalised melanoma genomic risk information trigger conversations about skin cancer prevention and skin examination with family, friends and health professionals?
    Br J Dermatol. 2017 Jun 19. doi: 10.1111/bjd.15744.
    PubMed     Abstract available


  156. KIM SK, Barker CA
    Outcomes of radiation therapy for advanced T3/T4 non-melanoma cutaneous squamous cell and basal cell carcinoma.
    Br J Dermatol. 2017 Jun 15. doi: 10.1111/bjd.15728.
    PubMed     Abstract available


  157. CERIO R, Moir G
    Palliative electrochemotherapy treatment of metastatic malignant melanoma.
    Br J Dermatol. 2017;176:1427.
    PubMed    


  158. JONES G
    Methotrexate increases the risk of melanoma: or does it?
    Br J Dermatol. 2017;176:1429-1430.
    PubMed    


    May 2017
  159. RIBERO S, Carrera C, Tell-Marti G, Pastorino C, et al
    Amelanotic melanoma in oculocutaneous albinism: a genetic, dermoscopic and reflectance confocal microscopy study.
    Br J Dermatol. 2017 May 27. doi: 10.1111/bjd.15687.
    PubMed     Abstract available


  160. SWETTER SM
    Challenges of treating melanoma in situ, lentigo maligna type: is pathological clearance the gold standard?
    Br J Dermatol. 2017;176:1115-1116.
    PubMed    


  161. ELLIS RA
    T-type calcium channels as potential biomarkers in melanoma.
    Br J Dermatol. 2017;176:1122.
    PubMed    


  162. KRENGEL S, Reyes-Mugica M
    Melanoma risk in congenital melanocytic naevi.
    Br J Dermatol. 2017;176:1114.
    PubMed    


    April 2017
  163. DIXON A, Steinman H, Anderson S, Nirenberg A, et al
    Routine usage of sentinel node biopsy in melanoma management must cease: reply from authors.
    Br J Dermatol. 2017 Apr 29. doi: 10.1111/bjd.15626.
    PubMed     Abstract available


  164. SALEH DB
    RE: Routine usage of sentinel node biopsy in melanoma management must cease.
    Br J Dermatol. 2017 Apr 29. doi: 10.1111/bjd.15619.
    PubMed     Abstract available


  165. ASGARI MM, Shen L, Sokil MM, Yeh I, et al
    Prognostics factors and survival in acral lentiginous melanoma.
    Br J Dermatol. 2017 Apr 22. doi: 10.1111/bjd.15600.
    PubMed     Abstract available


  166. ROCHA L, Menzies SW, Lo S, Avramidis M, et al
    Analysis of an electrical impedance spectroscopy system in short-term digital dermoscopy imaging of melanocytic lesions.
    Br J Dermatol. 2017 Apr 19. doi: 10.1111/bjd.15595.
    PubMed     Abstract available


  167. GUALANO MR, Osella-Abate S, Scaioli G, Marra E, et al
    Prognostic role of Histologic regression in primary cutaneous melanoma: A Systematic Review and Meta-analysis.
    Br J Dermatol. 2017 Apr 7. doi: 10.1111/bjd.15552.
    PubMed     Abstract available


  168. NIJSTEN T, Wakkee M
    The four Ws of skin cancer surveillance in patients with melanoma: Why? Who? When? Where?
    Br J Dermatol. 2017;176:839-841.
    PubMed    


  169. MONTAUDIE H, Pradelli J, Passeron T, Lacour JP, et al
    Pulmonary sarcoid-like granulomatosis induced by nivolumab.
    Br J Dermatol. 2017;176:1060-1063.
    PubMed     Abstract available


    March 2017
  170. LOTT JP, Wang Q, Titus LJ, Onega T, et al
    Temporal Trends in Healthcare Utilization following Primary Melanoma Diagnosis among Medicare Beneficiaries.
    Br J Dermatol. 2017 Mar 30. doi: 10.1111/bjd.15530.
    PubMed     Abstract available


  171. KARIMKHANI C, Green AC, Nijsten T, Weinstock MA, et al
    The Global Burden of Melanoma: Results from Global Burden of Disease Study 2015.
    Br J Dermatol. 2017 Mar 30. doi: 10.1111/bjd.15510.
    PubMed     Abstract available


  172. KOGUCHI-YOSHIOKA H, Okiyama N, Iwamoto K, Matsumura Y, et al
    Intravenous immunoglobulin contributes to control anti-melanoma differentiation-associated protein 5 (MDA5) antibody-associated dermatomyositis with palmar violaceous macules/papules.
    Br J Dermatol. 2017 Mar 27. doi: 10.1111/bjd.15499.
    PubMed     Abstract available


  173. LICCIARDELLO M, T Giura M, Rozzo G, Marra E, et al
    Arrhythmias in metastatic melanoma patient treated with targeted therapy and ICD implant.
    Br J Dermatol. 2017 Mar 10. doi: 10.1111/bjd.15447.
    PubMed     Abstract available


  174. RICHTIG G, Hoeller C, Kashofer K, Aigelsreiter A, et al
    Beyond the BRAFV600E hotspot - Biology and clinical implications of rare BRAF gene mutations in melanoma patients.
    Br J Dermatol. 2017 Mar 9. doi: 10.1111/bjd.15436.
    PubMed     Abstract available


    February 2017
  175. CORR M, Roulston G, King N, Dornan T, et al
    Living with 'melanoma'...for a day: a phenomenological analysis of medical students' simulated experiences.
    Br J Dermatol. 2017 Feb 23. doi: 10.1111/bjd.15402.
    PubMed     Abstract available


  176. TSAI S, Scott JF, Keller JJ, Gerstenblith MR, et al
    Cutaneous malignancies identified on an inpatient Dermatology consult service.
    Br J Dermatol. 2017 Feb 23. doi: 10.1111/bjd.15401.
    PubMed     Abstract available


  177. JORDAN M, Ghoreschi K
    Anti-melanoma differentiation-associated protein 5 autoantibodies as a marker for dermatomyositis-associated interstitial lung disease.
    Br J Dermatol. 2017;176:294-295.
    PubMed    


    January 2017
  178. WOLNER ZJ, Marghoob AA, Pulitzer MP, Postow MA, et al
    A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma.
    Br J Dermatol. 2017 Jan 28. doi: 10.1111/bjd.15354.
    PubMed     Abstract available


  179. VANHAECKE C, Deilhes F, Chanal J, Regnier-Rosencher E, et al
    BRAFV600 inhibitor discontinuation after complete response in advanced melanoma. A retrospective analysis of 16 patients.
    Br J Dermatol. 2017 Jan 27. doi: 10.1111/bjd.15345.
    PubMed     Abstract available


  180. KUNTE C, Letule V, Gehl J, Dahlstroem K, et al
    Electrochemotherapy in the treatment of metastatic malignant melanoma: A prospective cohort study by InspECT.
    Br J Dermatol. 2017 Jan 24. doi: 10.1111/bjd.15340.
    PubMed     Abstract available


  181. MINAGAWA A, Omodaka T, Koga H, Yokokawa Y, et al
    Nail apparatus melanoma thickness is associated with side and age.
    Br J Dermatol. 2017 Jan 24. doi: 10.1111/bjd.15318.
    PubMed     Abstract available


  182. KINSLER VA, O'Hare P, Bulstrode N, Calonje JE, et al
    Melanoma in congenital melanocytic naevi.
    Br J Dermatol. 2017 Jan 12. doi: 10.1111/bjd.15301.
    PubMed     Abstract available


    December 2016
  183. NEITTAANMAKI N, Salmivuori M, Polonen I, Jeskanen L, et al
    Hyperspectral imaging in detecting dermal invasion in lentigo maligna melanoma.
    Br J Dermatol. 2016 Dec 23. doi: 10.1111/bjd.15267.
    PubMed     Abstract available


  184. USHER-SMITH JA, Kassianos AP, Emery JD, Abel GA, et al
    Identifying people at higher risk of melanoma across the U.K.: a primary-care-based electronic survey.
    Br J Dermatol. 2016 Dec 23. doi: 10.1111/bjd.15181.
    PubMed     Abstract available


  185. HERMS F, Franck N, Kramkimel N, Fichel F, et al
    Neutrophilic eccrine hidradenitis in 2 patients treated with BRAF inhibitors: a new cutaneous adverse event.
    Br J Dermatol. 2016 Dec 22. doi: 10.1111/bjd.15259.
    PubMed     Abstract available


  186. RICHTIG G, Richtig E, Kashofer K, Koch L, et al
    Testing and clinical implications for non-V600 BRAF mutations in metastatic NRASmt melanoma.
    Br J Dermatol. 2016 Dec 7. doi: 10.1111/bjd.15222.
    PubMed     Abstract available


  187. LINOS E, Li WQ, Han J, Li T, et al
    Lifetime UV exposure and Lentigo Maligna Melanoma.
    Br J Dermatol. 2016 Dec 7. doi: 10.1111/bjd.15218.
    PubMed     Abstract available


  188. SPENDER LC, Inman GJ
    Fatal attractions? Correlations of CXCL12-CXCR4-CXCR7 expression with disease progression in melanoma and Kaposi sarcoma.
    Br J Dermatol. 2016;175:1140-1141.
    PubMed    


  189. YELAMOS O, Nehal KS
    Integrating clinical information, dermoscopy and reflectance confocal microscopy to improve the diagnostic accuracy and confidence of amelanotic and lightly pigmented melanomas.
    Br J Dermatol. 2016;175:1147-1148.
    PubMed    


  190. HAASS NK
    JNK-ERK signalling in melanoma: rewired or entangled?
    Br J Dermatol. 2016;175:1139-1140.
    PubMed    


  191. DIXON A, Steinman H, Anderson S, Nirenberg A, et al
    Routine usage of sentinel node biopsy in melanoma management must cease.
    Br J Dermatol. 2016;175:1340-1341.
    PubMed    


    November 2016
  192. SPEIGL L, Janssen N, Weide B, Pawelec G, et al
    Prognostic impact of the putative cancer stem cell markers ABCG2, CD133, ALDH1A1 and CD44V7/8 in metastatic melanoma.
    Br J Dermatol. 2016 Nov 21. doi: 10.1111/bjd.15194.
    PubMed     Abstract available


  193. MAHER NG, Blumetti TP, Gomes EE, Cheng HM, et al
    Melanoma diagnosis may be a pitfall for optical coherence tomography assessment of equivocal amelanotic or hypomelanotic skin lesions.
    Br J Dermatol. 2016 Nov 18. doi: 10.1111/bjd.15187.
    PubMed     Abstract available


  194. POLESIE S, Gillstedt M, Sonnergren HH, Osmancevic A, et al
    Methotrexate Treatment and Risk for Cutaneous Malignant Melanoma - a Retrospective Comparative Registry-based Cohort Study.
    Br J Dermatol. 2016 Nov 10. doi: 10.1111/bjd.15170.
    PubMed     Abstract available


  195. BARRETT JH
    Telomere length and melanoma - is there a straightforward relationship?
    Br J Dermatol. 2016;175:865-866.
    PubMed    


  196. ELLIKER KR, Williams HC
    Detection of skin cancer odours using dogs: a step forward in melanoma detection training and research methodologies.
    Br J Dermatol. 2016;175:851-852.
    PubMed    


  197. EISEMANN N
    Routine health data in skin cancer screening evaluation.
    Br J Dermatol. 2016;175:862.
    PubMed    


    October 2016
  198. RICHTIG G, Byrom L, Kupsa R, Schaider H, et al
    Pregnancy as driver for melanoma.
    Br J Dermatol. 2016 Oct 8. doi: 10.1111/bjd.15124.
    PubMed     Abstract available


  199. MAIQUES O, Macia A, Moreno S, Barcelo C, et al
    Immunohistochemical analysis of T-type calcium channels in acquired melanocytic nevi and melanoma.
    Br J Dermatol. 2016 Oct 8. doi: 10.1111/bjd.15121.
    PubMed     Abstract available


  200. O'SHEA SJ, Davies JR, Newton-Bishop JA
    Vitamin D, vitamin A, the primary melanoma transcriptome and survival.
    Br J Dermatol. 2016;175 Suppl 2:30-34.
    PubMed     Abstract available


    September 2016
  201. PIZZICHETTA MA, Kittler H, Stanganelli I, Ghigliotti G, et al
    Dermoscopic diagnosis of amelanotic/hypomelanotic melanoma.
    Br J Dermatol. 2016 Sep 28. doi: 10.1111/bjd.15093.
    PubMed     Abstract available


  202. WEINSTOCK MA, Lott JP, Wang Q, Titus LJ, et al
    Skin Biopsy Utilization and Melanoma Incidence among Medicare Beneficiaries.
    Br J Dermatol. 2016 Sep 17. doi: 10.1111/bjd.15077.
    PubMed     Abstract available


  203. LO MC, Maraka J, Garioch J, John WG, et al
    Monitoring vitamin D in the melanoma patient - impact of sun avoidance on vitamin D levels of melanoma patients at a tertiary UK referral melanoma service.
    Br J Dermatol. 2016 Sep 17. doi: 10.1111/bjd.15062.
    PubMed     Abstract available


  204. FOX J
    A changing treatment paradigm: the role of palliative care in metastatic melanoma.
    Br J Dermatol. 2016;175:462-3.
    PubMed    


    June 2016
  205. WANG CC, Tang CH, Wang CY, Huang SY, et al
    Risk of skin cancer in chronic haemodialysis patients: a nationwide, population-based study in Taiwan.
    Br J Dermatol. 2016 Jun 7. doi: 10.1111/bjd.14789.
    PubMed     Abstract available


    May 2016
  206. GUITERA P, Menzies SW, Argenziano G, Longo C, et al
    Dermoscopy and in vivo confocal microscopy are complimentary techniques for the diagnosis of difficult amelanotic and light colored skin lesions.
    Br J Dermatol. 2016 May 13. doi: 10.1111/bjd.14749.
    PubMed     Abstract available


  207. LLOYD-LAVERY A, Hodgson T, Coupe N, Bond S, et al
    Delayed oral toxicity from long-term vemurafenib therapy.
    Br J Dermatol. 2016;174:1159-60.
    PubMed    


  208. LALLAS A, Tschandl P, Kyrgidis A, Stolz W, et al
    Dermoscopic clues to differentiate facial lentigo maligna from pigmented actinic keratosis.
    Br J Dermatol. 2016;174:1079-85.
    PubMed     Abstract available


  209. GREVELING K, de Vries K, van Doorn MB, Prens EP, et al
    A two-stage treatment of lentigo maligna using ablative laser therapy followed by imiquimod: excellent cosmesis, but frequent recurrences on the nose.
    Br J Dermatol. 2016;174:1134-6.
    PubMed    


    April 2016
  210. NILSEN LT, Hannevik M, Veierod MB
    Ultraviolet exposure from indoor tanning devices: a systematic review.
    Br J Dermatol. 2016;174:730-40.
    PubMed     Abstract available


    March 2016
  211. PARTARRIEU-MEJIAS F, Perez-Velasquez F
    Image Gallery: Xeroderma pigmentosum.
    Br J Dermatol. 2016;174:e12.
    PubMed    


  212. DE VRIES K, Greveling K, Prens LM, Munte K, et al
    Recurrence rate of lentigo maligna after micrographically controlled staged surgical excision.
    Br J Dermatol. 2016;174:588-93.
    PubMed     Abstract available


  213. BELLON T, Lerma V, Gonzalez-Valle O, Gonzalez Herrada C, et al
    Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds.
    Br J Dermatol. 2016;174:621-4.
    PubMed     Abstract available


    February 2016
  214. LEE S, Duffy DL, McClenahan P, Lee KJ, et al
    Heritability of naevus patterns in an adult twin cohort from the Brisbane Twin Registry: a cross-sectional study.
    Br J Dermatol. 2016;174:356-63.
    PubMed     Abstract available


    January 2016
  215. KAI AC, Richards T, Coleman A, Mallipeddi R, et al
    Five-year recurrence rate of lentigo maligna after treatment with imiquimod.
    Br J Dermatol. 2016;174:165-8.
    PubMed     Abstract available


    August 2015
  216. CHAVEZ-BOURGEOIS M, Iglesias P, Brito J, Malvehy J, et al
    Skin cancers detected as casual findings with Reflectance Confocal Microscopy (RCM) in the assessment of melasma treatment.
    Br J Dermatol. 2015 Aug 12. doi: 10.1111/bjd.14066.
    PubMed     Abstract available


    June 2015
  217. BENATI E, Zalaudek I, Piana S, Argenziano G, et al
    In vivo detection of peripheral clefting in melanocytic lesions.
    Br J Dermatol. 2015 Jun 23. doi: 10.1111/bjd.13959.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: